Laura Hagerty

Interested in Neuromuscular Disease Research and Drug Development

[NCATS @ncats_nih_gov]

NCATS’ DRDRI Director Dominique Pichard, M.D., M.S., is moderating the 8th rare story of #RDDNIH! Eric Hoffman, Ph.D., of ReveraGen and Sharon Hesterlee, Ph.D., of @MDAorg are discussing how a public-private partnership brought vamorolone to the market.

[Duchenne UK @DuchenneUK]

Breaking news!
Vamorolone, the first treatment for all DMD patients regardless of ambulatory status has been approved in the UK! The drug (sold under the brand name Agamree) has been approved for the treatment of DMD in patients aged 4 yrs+ by the MHRA.
https://t.co/cRZzzRoOPr

[Laura Hagerty @Hagerty_Laura]

Congrats to MyoGene Bio CEO, Dr. Courtney Young, for receiving a Life Science Catalyst Award from @biocom!

[Biocom @Biocom]

We are pleased to announce this year's annual Life Science Catalyst Award recipients. 🏆 Join us in congratulating all 10 winners recognized for exceptional achievement and leadership in the California life science industry before the age of 40. Read more: https://t.co/gv21Q30n36

[Laura Hagerty @Hagerty_Laura]

Huge congrats to Courtney Young of MyoGene Bio for being named one of MIT @techreview 35 Innovators Under 35!!!!
https://t.co/cs9ZT4ojiN

[Laura Hagerty @Hagerty_Laura]

@ARPA_H is seeking input on future R&D investment ideas. Vote for 'Muscle-specific viruses' to help advance muscle targeted #genetherapy!!

[ARPA-H @ARPA_H]

🚨The #ARPAHDash Exceptional 8! 🚨
https://t.co/4z5WHQjWeD

[Rick Berke @rickberke]

EXCLUSIVE: Early findings in gene therapy death suggest CRISPR was not the cause https://t.co/1WwDH1Gx48 via @statnews @Jasonmmast

[Laura Hagerty @Hagerty_Laura]

@ARPA_H is seeking input on future R&D investment ideas. Vote for 'Muscle-specific viruses' to help advance muscle targeted #genetherapy!!

[ARPA-H @ARPA_H]

Get your favorite ideas to the next round. Discuss, debate, and vote today! #ARPAHDash

https://t.co/qt7g2wbpmc

[Polyplexus.com @polyplexors]

In the first matchup in the #ARPAHDash Proactive Health Focus Area @RezaSameni
with "Passive-Brain-Audition" is competing against
@lgrady00 with "Microbiome For Health".

In the second matchup Emily Raycroft with "CRISPR Powered Biosensors" is competing against Courtney Young with "Muscle-Specific Viruses".

Vote for your favorites at https://t.co/dTMk21JxBj

[Laura Hagerty @Hagerty_Laura]

@ARPA_H selected Courtney Young’s idea, “Muscle-specific viruses”, for the #ARPAHDash competition! Winners are chosen by the public, and voters are eligible for cash prizes. Online voting is open Apr 17-23. Please vote to support muscle targeting AAV! https://t.co/z4wnlFinsB

[Life Science Nation @LSciNation]

Congratulations to RESI Boston Innovator’s Pitch Challenge finalist, MyoGene Bio! Co-Founder & CEO, Courtney Young, will pitch to a panel of #investors September 21-22. Join RESI to cheer on our IPC finalists: https://t.co/YjOuaMDjuT

[Laura Hagerty @Hagerty_Laura]

@Matt_Muscle_Guy @MuscleAndNerve Much obliged, Matt!

[Laura Hagerty @Hagerty_Laura]

💵💰Funding opportunity in #Duchenne!!💰💵DMDRP has a $10M budget for Idea Development and Translational Research Awards. Submit your pre-applications by Aug 11th
https://t.co/DEISUGpkH4

[Laura Hagerty @Hagerty_Laura]

"Stunting of growth is a major concern of families and patients treated with #corticosteroids, and we are delighted to see this superiority of #vamorolone proven" said Paula Clemens MD, study co-chair at Univ of Pittsburgh. #glucocorticoids #Duchenne

[Laura Hagerty @Hagerty_Laura]

“The strength of evidence for both efficacy and safety of #vamorolone over such a wide dose range…allows clinicians to individually tailor treatment of #Duchenne patients” said Craig McDonald, MD, a professor at the University of California, Davis.

[Muscular Dystrophy News Today @mdnewstoday_]

New Post: Vamorolone Safely Improves Muscle Function in DMD Boys, Trial Finds https://t.co/ltueKi2Kju

[Lianna Orlando @LOrlandoScience]

.@Santhera and @ReveraGen announce 2.5-year Treatment Data with #Vamorolone in #Duchenne #DMD https://t.co/khPyQcdYr3

[Pfizer Inc. @pfizer_news]

We are proudly continuing our commitment to the #Duchenne muscular dystrophy community. Today, we announced the first participant was dosed in our Phase 3 investigational gene therapy trial for affected boys aged 4-7. https://t.co/0B0ddY8QE7

[Pharmacutical Daily @PharmacDaily]

ReveraGen Receives $3.3 Million NIH Commercialization Readiness Pilot Grant for NDA Preparations for Vamorolone in Duchenne Muscular Dystrophy https://t.co/AjF4oZzmxo

[CureDuchenne @CureDuchenne]

Exciting announcement from Santhera - Full enrollment of vamorolone’s VISION DMD trial. Subject to positive results of this first 24-week treatment period, this could pave the way for a regulatory submission to the US FDA in the fourth quarter of 2021

https://t.co/i5lRdPt493

[Laura Hagerty @Hagerty_Laura]

@Delta Why are your gate agents not wearing their masks? Face covers are required at all times in the Pittsburgh Airport.